Recently, the 5th International Green Zero-Carbon Festival and the 2026 ESG Leaders Summit were held in Shanghai. With the theme of "Practicing Green Development, Together Toward a Zero-Carbon Future," this year's Zero-Carbon Festival brought together more than 300 green benchmark enterprises and over 200 mainstream media outlets to jointly showcase the results of dual-carbon strategy practices. In the annual selection of the "2026 Zero-Carbon Awards," Xuanzhu Biopharma Technology Co., Ltd. (Stock Code: 2575.HK) won the "2026 ESG Practice Pioneer Award" for its systematic practices across the three major dimensions of environment, society, and corporate governance.

Xuanzhu Biopharma is an innovation-driven Chinese biopharmaceutical company with a global vision, focusing on major disease areas such as digestive system diseases, oncology, and NASH, and dedicated to the development of Class 1 new drugs with core independent intellectual property rights. The company deeply integrates the ESG concept into the entire chain of strategy and operations, establishes a scientific and well-developed ESG governance system, incorporates environmental protection, social responsibility, and compliance governance into its core decision-making processes, and helps realize the beautiful vision of "innovation-driven, boosting the development of China's new drugs, and serving human health." At the environmental level, the company continues to make efforts around energy conservation and consumption reduction, wastewater and waste gas treatment, and waste management, achieves its quantitative emission reduction targets as scheduled, actively responds to climate change risks, and helps realize the national "dual-carbon" goals; at the social level, with patient needs at the core, it accelerates innovative drug R&D, promotes more Class 1 new drugs to benefit a wide range of patients, and at the same time pays attention to employee rights and the co-construction of the industry ecosystem; at the governance level, it adheres to business ethics, improves compliance management systems, promotes the concept of green procurement, extends ESG requirements to all links of the supply chain, and jointly builds a transparent and trustworthy business ecosystem.

Looking ahead, Xuanzhu Biopharma will take this honor as a new starting point and continue to deepen ESG practices and the layout of green and low-carbon strategies. The company will further advance the construction of a carbon emission reduction management and control system, expand the coverage of greenhouse gas accounting, and explore new models of green R&D and low-carbon operations; accelerate the process of innovative drug R&D, promote more high-quality drugs to benefit patients, and facilitate the high-quality development of the biopharmaceutical industry; and continuously improve the compliance governance system and ESG information disclosure mechanism, repaying the trust of investors and the public with a higher standard of transparent governance. The company is well aware that sustainable development is the cornerstone of long-term value creation for an enterprise, and with a development philosophy in which scientific innovation and responsible commitment complement each other, it will join hands with all parties to move toward a zero-carbon future.